Lactobacillus sakei WIKIM0109, a lactic acid bacterium in kimchi, with the efficacy of alleviating arthritis

Abstract

The present invention relates to a novel Lactobacillus sakei WIKIM0109 isolated from kimchi and a composition containing the same. The Lactobacillus sakei WIKIM0109 of the present invention is a lactic acid bacterium having the activities of inhibiting the production of IgG and IgG2a in blood and inhibiting the production of IFN-γ, IL-17 and TNF-α, and can be applied in various ways for the prevention or improvement of arthritis in humans or animals, intestinal regulation and other uses.

Description

Technical Field

[0001] The present invention relates to a novel Lactobacillus sakei strain and a composition containing the same. Background Art

[0002] Rheumatoid arthritis is an autoimmune and chronic inflammatory disease with a prevalence of 1% to 1.5%. Inflammatory changes in joints induce systemic joint edema and pain, and if it worsens, it may lead to serious consequences such as joint deformity and difficulty in joint flexion.

[0003] So far, the direct cause of arthritis has not been clearly identified, and various therapeutic agents such as steroids, non-steroidal anti-inflammatory drugs, gout inhibitors, and immunosuppressants are used to treat arthritis. However, these therapeutic agents do not show a fundamental therapeutic effect and are limited in their use due to various side effects. Also, some chemotherapy drugs have drawbacks such as a lack of efficacy against already developed arthritis.

[0004] Therefore, there is a need to develop an arthritis therapeutic agent that is effective in relieving inflammatory symptoms and pain, has few treatment side effects, and is easy to take. Accordingly, in the present invention, a lactic acid bacterium derived from kimchi that effectively relieves arthritis symptoms and inhibits the production of inflammation-related factors in the blood was studied.

[0005] Prior Art Documents

[0006] Patent Documents

[0007] Patent Document 1: Korean Patent Publication No. 10-2018-0104544 Summary of the Invention

[0008] Technical Problem

[0009] An object of the present invention is to provide a novel Lactobacillus bacterium having excellent arthritis-improving activity.

[0010] Solution to the Problem

[0011] Accordingly, the present inventors attempted to find a strain having an arthritis-improving effect, and as a result, a novel Lactobacillus sakei strain, Lactobacillus sakei WIKIM0109, was isolated and identified, thereby completing the present invention.

[0012] Lactobacillus sakei WIKIM0109 of the present invention is a novel strain of Lactobacillus sakei derived from kimchi. Although Lactobacillus sakei WIKIM0109 in the present invention was isolated and identified from kimchi, its acquisition route is not limited thereto.

[0013] Analysis results of 16S rRNA base sequences for microbial identification and classification showed that the lactic acid bacteria strains isolated from traditional fermented foods in the examples of the present invention have the nucleotide sequence of SEQ ID NO: 1.

[0014] Therefore, the microorganism of the present invention having the 16S rRNA base sequence of SEQ ID NO: 1 was named Lactobacillus sakei WIKIM0109 and was deposited at the Biological Resource Center on March 7, 2019 (deposit number KCTC13818BP).

[0015] The strain Lactobacillus sakei WIKIM0109 (Lactobacillus sakei WIKIM0109; deposit number KCTC13818BP) of the present invention is a Gram-positive bacterium and is a facultative anaerobe that can grow under both aerobic and anaerobic conditions, in the form of bacilli.

[0016] Lactobacillus sakei WIKIM0109 of the present invention has the general intestinal regulation effect and immune enhancement effect of lactic acid bacteria. It is well known that lactic acid bacteria of the genus Lactobacillus have intestinal regulation effect and immune enhancement effect.

[0017] In the following examples, it was confirmed that Lactobacillus sakei WIKIM0109 of the present invention inhibits the production of IgG and IgG2a in the blood and inhibits the production of IFN-γ, IL-17 and TNF-α, and thus has an effect of improving arthritis. Therefore, Lactobacillus sakei WIKIM0109 of the present invention can be applied in various ways to uses such as intestinal regulation, arthritis improvement, and immune enhancement of humans or animals.

[0018] Therefore, in a specific example of the present invention, there is provided a composition comprising Lactobacillus sakei WIKIM0109, its culture, its lysate or its extract as an active ingredient.

[0019] Lactobacillus sakei WIKIM0109 contained in the composition of the present invention can exist in the form of live bacteria, and can also exist in a dried or freeze-dried form. The forms and formulation methods of lactic acid bacteria suitable for inclusion in various compositions are well known to those of ordinary skill in the art to which the present invention pertains.

[0020] In a specific example, the above composition may be a composition for oral administration, which contains the Lactobacillus sakei WIKIM0109 strain in the form of live bacteria.

[0021] Moreover, in a specific example of the present invention, there is provided an intestinal regulator composition comprising Lactobacillus sakei WIKIM0109, its culture, its lysate or its extract as an active ingredient. The intestinal regulator composition of the present invention can be used for preventing, treating and improving gastrointestinal diseases in animals including humans. Preferably, the above animals include livestock such as cattle, horses, pigs, etc. The above "gastrointestinal diseases" include all harmful bacterial infections and inflammatory bowel diseases of the gastrointestinal tract, such as infectious diarrhea, gastrointestinal inflammation, inflammatory bowel disease, neuroenteritis syndrome, small intestinal microbial overgrowth, acute intestinal diarrhea, etc. caused by pathogenic microorganisms (Escherichia coli, Salmonella, Clostridium, etc.), but are not limited thereto.

[0022] The intestinal regulator composition of the present invention is preferably administered orally. The dosage may vary depending on the type of gastrointestinal disease, the degree of the disease, age, gender, race, treatment or prevention purpose, etc. Generally, based on adults, 10 million to 100 billion can be administered per day.

[0023] The present invention provides a composition for enhancing immunity, comprising Lactobacillus sakei WIKIM0109, its culture, its lysate or its extract as an active ingredient. It is well known that lactic acid bacteria of the genus Lactobacillus have an immune-enhancing effect.

[0024] The present invention provides a composition for preventing and improving arthritis, comprising Lactobacillus sakei WIKIM0109, its culture, its lysate or its extract as an active ingredient. The above arthritis can be one or more diseases selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis or psoriatic arthritis, but is not limited thereto.

[0025] In a specific example, the above arthritis can be rheumatoid arthritis.

[0026] Due to this beneficial effect, Lactobacillus sakei WIKIM0109 of the present invention can be included in pharmaceuticals, health functional foods, foods, feeds, feed additives or lactic acid bacteria starters for fermenting foods or feeds.

[0027] In a specific example, when the composition of the present invention is used as a pharmaceutical composition, the pharmaceutical composition of the present invention can be prepared by using pharmaceutically suitable and physiologically acceptable adjuvants in addition to the above active ingredients. As the above adjuvants, excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, glidants or flavoring agents, etc. can be used.

[0028] For administration, in addition to the above active ingredients, the above pharmaceutical composition can further comprise one or more pharmaceutically acceptable carriers to be preferably formulated into a pharmaceutical composition.

[0029] For example, in order to formulate in the form of tablets or capsules, the active ingredient can be combined with oral, non-toxic, pharmaceutically acceptable inert carriers such as ethanol, glycerol, water, etc. And, according to expectation or need, suitable binders, lubricants, disintegrants and colorants can also be included as a mixture. Suitable binders include, but are not limited to, starch, gelatin, natural sugars such as glucose or β-lactose, corn sweeteners, natural gums such as gum arabic, tragacanth or sodium oleate and synthetic gums, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, etc. For compositions formulated as liquid solutions, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextran solution, maltodextrin solution, glycerol, ethanol and more than one of these components can be mixed and used as pharmaceutically acceptable carriers suitable for sterile and biological use. Other conventional additives such as antioxidants, buffers, bacteriostatic agents, etc. can be added as needed. And further diluents, dispersants, surfactants, binders and lubricants are added to formulate injectable dosage forms such as aqueous solutions, suspensions, emulsions, pills, capsules, granules or tablets.

[0030] Furthermore, as a suitable method in this field, the methods disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA can be used and can be preferably formulated according to each disease or ingredient.

[0031] In another specific example, the present invention can be a food for preventing and improving arthritis containing Lactobacillus sakei WIKIM0109, its culture, its lysate or its extract as an active ingredient. The above food composition can include forms such as health functional foods or beverages, stick foods, etc.

[0032] In the present invention, food compositions containing the above strains as active ingredients can include beverages such as fermented milk. Therefore, the present invention provides a lactic acid bacteria starter for fermented foods or feeds, containing Lactobacillus sakei WIKIM0109, its culture, its lysate or its extract as an active ingredient.

[0033] The food composition of the present invention can be formulated in the same manner as the above pharmaceutical composition to be used as a functional food, or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, vitamin complexes, health foods, etc.

[0034] The food composition of the present invention may contain ingredients commonly added during food preparation, such as proteins, carbohydrates, fats, nutrients, flavoring agents, and flavor enhancers. Examples of the above-mentioned carbohydrates include monosaccharides such as glucose, fructose, etc.; disaccharides such as maltose, sucrose, oligosaccharides, etc.; and polysaccharides such as conventional sugars like dextrin, cyclodextrin, etc. and sugar alcohols like xylitol, sorbitol, erythritol, etc. As flavor enhancers, natural flavor enhancers (thaumatin, stevia extract (such as rebaudioside A, glycyrrhizin, etc.)) and synthetic flavor enhancers (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is made into beverages and drinks, it may further contain citric acid, fruit syrup, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts.

[0035] The above-mentioned composition of the present invention can be used as a feed additive or feed.

[0036] When used as a feed additive, the above-mentioned composition can be made into a high-concentration solution, powder, or granule form of 20% to 90%. The above feed additive may further contain one or more of organic acids such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid, etc. or phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphates (polymeric phosphates), etc. or natural antioxidants such as polyphenols, catechins, α-tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, phytic acid, etc. When used as feed, the above-mentioned composition can be formulated into a conventional feed form and can contain conventional feed ingredients together.

[0037] The above feed additive and feed may also contain grains such as crushed or broken wheat, oats, barley, corn, and rice; plant protein feeds such as feeds containing rapeseed, soybean, sunflower as the main components; animal protein feeds such as blood meal, meat meal, bone meal, and fish meal; sugar, and dairy products such as dry components composed of various milk powders and whey powders, etc. In addition, it may also contain nutritional supplements, digestion and absorption enhancers, growth promoters, etc.

[0038] The above feed additive can be administered alone or in combination with other feed additives to animals in an edible carrier. Moreover, the above feed additive can be directly mixed into animal feed as a top dressing, or can be easily administered to animals as an oral dosage form separate from the feed. When the above feed additive is administered separately from animal feed, it can be combined with a pharmaceutically acceptable edible carrier well-known in the art to prepare an immediate-release or sustained-release preparation. These edible carriers can be solid or liquid, such as corn starch, lactose, sucrose, soybean flakes, peanut oil, olive oil, sesame oil, and propylene glycol. When using a solid carrier, the feed additive can be in the form of tablets, capsules, powders, lozenges, sugar-coated tablets, or top dressings in a non-dispersed form. When using a liquid carrier, the feed additive can be in the form of soft gelatin capsules, syrups, suspensions, emulsions, or solutions.

[0039] Moreover, the above feed additive and feed can contain adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, solubilizers, etc. The above feed additive can be added to animal feed by means of impregnation, spraying, or mixing.

[0040] The feed or feed additive of the present invention can be applicable to the feed of various animals including mammals, poultry, and fish.

[0041] The above mammals can include not only pigs, cows, sheep, goats, and laboratory rodents, but also pets (such as dogs, cats), etc. The above poultry can include chickens, turkeys, ducks, geese, pheasants, and quails, etc. The above fish can include trout, etc., but are not limited thereto.

[0042] Based on a single dose, the amount of Lactobacillus sakei strain WIKIM0109 contained in the composition of the present invention can be about 10 6 cfu / g to 10 12 cfu / g, such as 10 7 cfu / g to 10 11 cfu / g, 10 8 cfu / g to 10 10 cfu / g. When administering the strain, it is preferably administered in a live bacterial cell state, and can be administered in a state of being killed or attenuated before ingestion. Moreover, when using a culture supernatant, etc. for preparation, a sterilization process through a heat treatment process can be further carried out. The amount of the strain required to achieve the minimum efficacy and the daily intake level can vary according to the physical or health condition of the ingestor, but generally can be about 10 6 cfu / g to 10 12 cfu / g, such as 10 7 cfu / g to 10 11 cfu / g, 10 8 cfu / g to 1010 cfu / .

[0043] Advantages and features of the present invention and methods for achieving them will become apparent with reference to the embodiments described in detail below. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in various different forms. These embodiments are only provided for the completeness of the disclosure of the present invention and to fully inform those of ordinary skill in the art to which the present invention pertains of the scope of the invention. The present invention is only defined by the scope of the claims.

[0044] Effects of the Invention

[0045] Lactobacillus sakei WIKIM0109 of the present invention has the activity of inhibiting the production of IgG and IgG2a in the blood and the activity of inhibiting the production of IFN-γ, IL-17 and TNF-α. Therefore, as a lactic acid bacterium, it can be applied in various ways to the intestinal regulation, immune enhancement, prevention or improvement of gastrointestinal diseases and arthritis of humans or animals. Furthermore, it can be effectively used as a fermentation starter for fermentation.

[0046] Lactobacillus sakei WIKIM0109 of the present invention is a lactic acid bacterium isolated from kimchi and has the activity of inhibiting the production of IgG and IgG2a in the blood and the activity of inhibiting the production of IFN-γ, IL-17 and TNF-α. Therefore, it can be applied in various ways to the prevention or improvement of arthritis. Furthermore, it can be effectively used as a fermentation starter for fermentation. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] Figure 1 To show the results of the arthritis incidence and arthritis index of a mouse model orally administered with the strain of the present invention.

[0048] Figure 2 To show the results of measuring the foot thickness induced by arthritis in a mouse model orally administered with the strain of the present invention.

[0049] Figure 3 To show the results of measuring the production levels of IgG and collagen-specific IgG (CII-IgG) in the blood.

[0050] Figure 4 To show the results of measuring the production levels of IgG2a and collagen-specific IgG2a (CII-IgG2a) in the blood.

[0051] Figure 5 To show the results of measuring the production levels of collagen antigen-specific IFN-γ, IL-17 and TNF-α.

[0052] Figure 6 To show the results of a comparative experiment on the immunomodulatory ability of WIKIM0109 and other Lactobacillus sakei strains LS35 and LS41. Detailed implementation mode

[0053] Hereinafter, the present invention will be described in detail by way of examples. The following examples are only used to illustrate the present invention, but the scope of the present invention is not limited to the following examples.

[0054] Example

[0055] Example 1: Isolation and identification of strains

[0056] The single colonies obtained by smearing the stock solution of the kimchi extract on MRS medium were collected using a loop and cultured in MRS broth. DNA extraction was performed using the QIAamp DNA Mini Kit (QIAgen, Germany). The extracted DNA was confirmed with 1% agarose. To amplify the 16S rRNA gene, PCR was performed using the extracted genomic DNA as a template. The PCR conditions were 30 cycles of denaturation at 95°C for 1 minute, annealing at 45°C for 1 minute, and extension at 72°C for 1 minute and 30 seconds. The sequence of the obtained PCR product was analyzed by Macrogen (Seoul, Korea). The identification of bacteria was performed by similarity analysis of the 16S rRNA sequence using the Basic Local Alignment Search Tool (BLAST) search engine of the National Center for Biotechnology Information (NCBI, www.ncbi.nlm.nih.gov).

[0057] As a result of the 16S rRNA base sequence analysis for microorganism identification, it was found that the strain isolated through the examples of the present invention has the nucleotide sequence of SEQ ID NO: 1.

[0058] Therefore, the microorganism of the present invention was named Lactobacillus sakei WIKIM0109 and was deposited at the Biological Resource Center on March 7, 2019 (deposit number KCTC13818BP).

[0059] Example 2: Confirmation of the efficacy of Lactobacillus sakei WIKIM0109 in improving arthritis

[0060] The Lactobacillus sakei WIKIM0109 strain isolated in Example 1 above was cultured in MRS medium at 30°C for 24 hours. The cultured cells were centrifuged at 8000 rpm for 5 minutes, washed with PBS to remove the remaining culture medium components. Then, the number of bacteria was quantified to 1×10 using PBS. 10CFU / ml. 0.1 ml (1x10 9 CFU) was orally administered to the collagen-induced arthritis mouse model 5 times a week using a probe. At this time, sterile PBS was administered to the negative control group and the positive control group.

[0061] 1) Determination of arthritis incidence and index in collagen-induced arthritis mouse model

[0062] The arthritis score and incidence rate during the 12 weeks when the Lactobacillus sakei WIKIM0109 strain was orally administered to the collagen-induced arthritis mouse model are shown in Figure 1 .

[0063] As a result, the incidence rate and arthritis score of the collagen-induced arthritis induction control group (CIA-No LAB) were the highest, and it was confirmed that the incidence rate and arthritis score of the Lactobacillus sakei WIKIM0109 treatment group (WIKIM0109) were significantly reduced.

[0064] 2) Sensory evaluation and determination of foot thickness

[0065] Four weeks after orally administering the Lactobacillus sakei WIKIM0109 strain to the experimental animals, the arthritis was evaluated by clinical visual assessment method and the foot thickness was measured.

[0066] As a result, as Figure 2 shown, compared with the normal group (Naive), symptoms such as erythema and swelling could be confirmed in the joints and fingers, which were the sensory evaluation criteria, in the collagen-induced arthritis induction control group (CIA-NoLAB). It was confirmed that the erythema and joint swelling were alleviated in the Lactobacillus sakei WIKIM0109 treatment group (WIKIM0109), and the foot thickness was reduced compared with the control group.

[0067] 3) Determination of IgG and IgG2a concentrations in blood

[0068] The blood of the experimental animals was collected, and the concentrations of IgG, collagen antigen-specific IgG and IgG2a, and collagen antigen-specific IgG2a in the blood were measured. Figure 3 As a result of measuring the concentrations of IgG and collagen antigen-specific IgG (CII-IgG), Figure 4 As a result of measuring the concentrations of IgG2a and collagen antigen-specific IgG2a (CII-IgG2a).

[0069] Table 1

[0070] Before administration After administration Inhibition rate (%) IgG 6.52 ± 0.81 mg / ml 4.796 ± 1.08 mg / ml 26.5 CII-IgG 14.04 ± 1.51 μg / ml 3.77 ± 2.21 μg / ml 73.2 IgG2a 118.2 ± 19.55 μg / ml 57.65 ± 9.02 μg / ml 51.3 CII-IgG2a 16.17 ± 0.88 μg / ml 11.26 ± 2.34 μg / ml 30.4

[0071] As Figure 3As shown in Table 1, it was confirmed that compared with the normal group, the production of IgG and IgG2a in the blood was promoted when arthritis was induced, and it was confirmed that when Lactobacillus sakei WIKIM0109 was administered to experimental animals, the concentrations of IgG and IgG2a were decreased. It was confirmed that especially in the case of collagen antigen-specific IgG2a (CII-IgG2a), the production was significantly inhibited by about 30.4% compared with the control group.

[0072] 4) Determination of production concentrations of collagen antigen-specific IFN-γ, IL-17 and TNF-α

[0073] Peripheral lymph nodes around the joints of experimental animals were collected to obtain single cells. After dispensing 5×10 5 cells per well into a 96-well plate, the production concentrations of antigen-specific IFN-γ, IL-17 and TNF-α were measured using the supernatant treated with collagen (50 μg / ml) for 48 hours. As Figure 5 shown, it was found that compared with the normal group, the production of antigen-specific IFN-γ, IL-17 and TNF-α in the arthritis-induced group increased, and it was confirmed that when Lactobacillus sakei WIKIM0109 was administered to experimental animals, the production of antigen-specific IFN-γ, IL-17 and TNF-α decreased significantly.

[0074] 5) Comparative experiment of WIKIM0109 and other species of Lactobacillus sakei

[0075] In order to confirm whether the effect of Lactobacillus sakei WIKIM0109 above was a general effect of Lactobacillus sakei, Lactobacillus sakei LS35 and LS41 owned by the World Institute of Kimchi affiliated with the Korea Food Research Institute were compared in terms of ① increased production amount of immunosuppressive cytokine IL-10 and ② decreased production amount of immune-enhancing cytokine IL-17.

[0076] Lactobacillus sakei LS35 was isolated from sujeotgal, and Lactobacillus sakei LS41 was isolated from scallion / mustard kimchi. They were statically cultured in Lactobacillus MRS (BD Difco) liquid medium in an incubator at 30 °C for 24 hours. After analyzing the sequence of the gene encoding 16S rRNA, through homology analysis using the Basic Local Alignment Search Tool (BLAST) of the National Center for Biotechnology Information (NCBI) in the United States, it was identified as Lactobacillus sakei.

[0077] OT-II mice with OVA-specific T cells were purchased from Jackson Laboratory and used after breeding. 5×10 5Single splenocytes from OT-II mice were dispensed into 96-well plates. After treatment with OVA peptide (OVA323-339) and Lactobacillus sakei isolated from kimchi at an MOI of 1, they were cultured at 37 °C for 72 hours. The amounts of IL-17 and IL-10 present in the culture medium were processed using the Mouse Th1 / Th2 / Th17 kit of the Cytometric Bead Array (CBA) for multiplexed quantification of low-volume samples purchased from BD Bioscience and according to the recommended method. After measurement using FACSCanto II (BD Bioscience), the production amount of each cytokine was analyzed based on the standard curve.

[0078] The experimental results confirmed that, compared with other species of Lactobacillus sakei, when treated with WIKIM0109, higher production of IL-10, the lowest production of IL-17, and the highest IL-10 / IL-17 ratio were measured ( Figure 6 ).

[0079] For the immunosuppressive cytokine IL-10, the LS41 strain also showed an increase in production, but WIKIM0109 showed an increase in IL-10 production of about 40% or more. In the case of LS35, only about 1 / 3 of that of WIKIM0109 was produced.

[0080] Furthermore, it was confirmed that for the immunostimulatory cytokine IL-17, the LS41 strain did not show a significant decrease in production, while WIKIM0109 showed a significant decrease in IL-17 production. On the contrary, it was confirmed that in the case of LS35, even for the same strain of Lactobacillus sakei, the production of IL-17 increased instead.

[0081] The specific parts of the present invention have been described in detail above. For those of ordinary skill in the art, these specific techniques are only preferred examples, and obviously the scope of the present invention is not limited thereto. Therefore, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

[0082] Deposit number

[0083] Name of the depository institution: Korea Collection for Type Cultures (International)

[0084] Deposit number: KCTC13818BP

[0085] Date of deposit: 20190307

[0086] Translation

[0087] Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure

[0088] International format

[0089] Certificate of Deposit of Original Deposit

[0090] Depositor: Korea Food Research Institute

[0091] Address: 245 Nongsaengmyeong-ro, Iseo-myeon, Wanju-gun, Jeollabuk-do, Korea

[0092]

[0093]

[0094] Form BP / 4 (KCTC Form 17). <110> Korea Food Research Institute <120> Lactobacillus sakei WIKIM0109, a kimchi lactic acid bacterium with the efficacy of alleviating arthritis <130> PCT677 <150> KR 10-2019-0034211 <151> 2019-03-26 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1409 <212> DNA <213> Unknown <220> <223> Lactobacillus sakei <400> 1 agtcgaacgc actctcgttt agattgaagg agcttgctcc tgattgataa acatttgagt 60 gagtggcgga cgggtgagta acacgtgggt aacctgccct aaagtggggg ataacatttg 120 gaaacagatg ctaataccgc ataaaaccta acaccgcatg gtgtagggtt gaaagatggt 180 ttcggctatc actttaggat ggacccgcgg tgcattagtt agttggtgag gtaaaggctc 240 accaagaccg tgatgcatag ccgacctgag agggtaatcg gccacactgg gactgagaca 300 cggcccagac tcctacggga ggcagcagta gggaatcttc cacaatggac gaaagtctga 360 tggagcaacg ccgcgtgagt gaagaaggtt ttcggatcgt aaaactctgt tgttggagaa 420 gaatgtatct gatagtaact gatcaggtag tgacggtatc caaccagaaa gccacggcta 480 actacgtgcc agcagccgcg gtaatacgta ggtggcaagc gttgtccgga tttattgggc 540 gtaaagcgag cgcaggcggt ttcttaagtc tgatgtgaaa gccttcggct caaccgaaga 600 agtgcatcgg aaactgggaa acttgagtgc agaagaggac agtggaactc catgtgtagc 660 ggtgaaatgc gtagatatat ggaagaacac cagtggcgaa ggcggctgtc tggtctgtaa 720 ctgacgctga ggctcgaaag catgggtagc aaacaggatt agataccctg gtagtccatg 780 ccgtaaacga tgagtgctag gtgttggagg gtttccgccc ttcagtgccg cagctaacgc 840 attaagcact ccgcctgggg agtacgaccg caaggttgaa actcaaagga attgacgggg 900 gcccgcacaa gcggtggagc atgtggttta attcgaagca acgcgaagaa ccttaccagg 960 tcttgacatc ctttgaccac tctagagata gagctttccc ttcggggaca aagtgacagg 1020 tggtgcatgg ttgtcgtcag ctcgtgtcgt gagatgttgg gttaagtccc gcaacgagcg 1080 caacccttat tactagttgc cagcatttag ttgggcactc tagtgagact gccggtgaca 1140 aaccggagga aggtggggac gacgtcaaat catcatgccc cttatgacct gggctacaca 1200 cgtgctacaa tggatggtac aacgagttgc gagaccgcga ggtttagcta atctcttaaa 1260 accattctca gttcggattg taggctgcaa ctcgcctaca tgaagccgga atcgctagta 1320 atcgcggatc agcatgccgc ggtgaatacg ttcccgggcc ttgtacacac cgcccgtcac 1380 accatgagag tttgtaacac ccaaagccg 1409

Claims

1. Lactobacillus sakei WIKIM0109 with the deposit number KCTC13818BP.

2. A pharmaceutical composition for preventing or treating inflammatory arthritis, characterized in that, It contains Lactobacillus sakei WIKIM0109 with the deposit number KCTC13818BP as an active ingredient.

3. The pharmaceutical composition according to claim 2, characterized in that, Inflammatory arthritis is rheumatoid arthritis, ankylosing spondylitis, osteoarthritis or psoriatic arthritis.

4. The pharmaceutical composition according to claim 2, characterized in that, The above composition reduces the allergic inflammatory response by inhibiting the production of IgG and IgG2a in the blood.

5. The pharmaceutical composition according to claim 2, characterized in that, The above composition reduces the allergic inflammatory response by inhibiting the production of collagen antigen-specific IFN-γ, IL-17 and TNF-α.

6. The pharmaceutical composition according to claim 2, characterized in that, The above composition is a composition for oral administration.

7. A feed or feed additive composition, characterized in that, It contains Lactobacillus sakei WIKIM0109 with the deposit number KCTC13818BP as an active ingredient.

Images